A global biotech startup in the exosome field is getting worldwide attention with its excellent technology and feasibility.
ExoCoBio Inc. has been named one of the ‘Top 4 Most Richly Funded Exosome Startups’ announced by ‘BioInformant’, a global market research company specialized in stem cells.
ExoCoBio Inc. succeeded in a Series A investment totaling KRW 12.5 billion within only about 100 days of its foundation in April 2017. Following this, they published a thesis confirming the feasibility of stem cell-derived exosomes for atopic dermatitis improvement, and successfully completed a KRW 30 billion Series B investment in September 2018. This ranks as the number 1 funding track record in Korea and 3rd in worldwide investment performance within the exosome sector.
Moreover, in August 2018, ExoCoBio Inc. launched the derma-cosmetic brand ‘Celltweet’, which contains ASC-EXOSOME™, a patent-applied ingredient. ‘Celltweet’ is a compound word combining ‘cell’ and ‘tweet’, reflecting the concept that exosomes—the cellular messengers—can quickly resolve various skin stresses.
Source: BusinessNewsWire (October 3, 2018)
LINK